Drug discovery

#Biomarkers #Drug discovery #Evotec #Webinar

Webinar: From PK/PD and biomarkers to decision-making

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

#News

Genomics
#Clinical trials #Drug discovery #Genetics / genomics #Multiomics

Designing multiomics studies to capture biological response

Dr Shi-qi An and Dr Naira Movsisyan of Novogene Europe consider why multiomics studies should follow biological responses over time, and how carefully chosen sampling points can distinguish initiating mechanisms from adaptation, compensation and the molecular signatures left by surviving cells.  In drug discovery, a compound is often assessed by… Read More

#Exclusive Content

GPCRs
#Drug activity #Drug development #Drug discovery #GPCR

Last chance to register: Improving the predictive power of GPCR assays

The pharmacological behaviour of drugs is determined not only by their intrinsic properties but also by the sensitivity of the biological systems in which they are evaluated. Variations in receptor density and signal transduction efficiency can significantly influence observed drug responses, complicating the translation of in vitro findings to in… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Clinical research #Clinical trials #Data standardisation #Drug discovery

The evolution of AI agents in drug discovery

Partha Anbil and Satish Tadikonda explore the current state of AI agents in drug discovery, with a specific focus on clinical data harmonisation, the transition to autonomous laboratories, and the projected market growth that underscores this technological revolution.  Introduction: The dawn of agentic AI  Drug… Read More

#Exclusive Content

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

Last chance to register: How AI agents are accelerating R&D

R&D teams don’t need another chatbot. They need a team that can act on their behalf, guided by the scientists who know the science best. The future of R&D removes the toil of day-to-day work and connects the data scattered across your systems and teams. In this webinar, taking place… Read More

#News

#Biotechnology #Cancer research #Clinical trials #Drug development #Drug discovery #Investment #Technology #Tumours

This week in Drug Discovery (19-23 October)

News round-up for 19-23 October 2026 by Megan Thomas, Multimedia Editor at DDW.  In this week’s news roundup, drug discovery and biopharma companies continue to make progress across the drug development pipeline, with recent updates highlighting clinical trial milestones, emerging research and investment in new treatments. The… Read More

#News

T cell engagers
#Cell Science #Drug discovery #T cell engagers #Whitepaper

Whitepaper – T-cell engagers: From drug discovery hurdles to next-gen solutions

Read this new Whitepaper from WuXi Biologics. Innovative platforms across key stages of TCE drug discovery, with real-world case studies on high-purity production and fit-for-purpose in vitro & in vivo studies. Proven approaches to navigate key development challenges, such as structural complexity, CRS risks, and tumour heterogeneity. Forward-looking strategies combining… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #FAIR Principles

Building strong data foundations for multimodal drug discovery

As drug discovery spans more modalities and more AI driven workflows, research teams face a growing challenge in keeping data connected and meaningful as it moves between people, systems and organisations. Here, Janice Darlington, Director of Customer Engagement at Collaborative Drug… Read More

#Exclusive Content

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

Webinar: How AI agents are accelerating R&D

R&D teams don’t need another chatbot. They need a team that can act on their behalf, guided by the scientists who know the science best. The future of R&D removes the toil of day-to-day work and connects the data scattered across your systems and teams. In this webinar, taking place… Read More

#News

#Drug discovery #Lightcast Discovery #Single-cell analysis

Bringing functional single-cell analysis into drug discovery 

Sarah Taylor, VP of Science at Lightcast, discusses how functional single-cell analysis can complement existing technologies, improve early-stage drug discovery decisions and help researchers identify promising candidates by measuring what cells do.  DDW: You spent nearly nine years at 10x Genomics taking genomic technologies from concept to launch, and… Read More

#Exclusive Content

#Biomarkers #Drug discovery #Evotec #Webinar

Webinar explores how modeling shapes clinical strategy

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

#News

#Biomarkers #Drug discovery #Evotec #Webinar

From PK/PD and Biomarkers to decision-making: How modeling shapes clinical strategy

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

Webinar date:
Supported by Evotec
#Featured Webinars #Webinars